Myeloid CD209 Drives Tumor Immune Evasion and Resistance to PD-1 Blockade Through ICAM-2–Mediated T-Cell Mechanosuppression
Resistance to PD-1–based immunotherapy remains a major challenge in cancer treatment, especially in immunologically “cold” tumors characterized by T-cell exclusion and impaired T-cell effector function. Mechanical processes impact T-cell activity, and mechanical perturbations may represent a distinct mode of immune suppression. Here, we identified CD209, a myeloid-expressed C-type lectin receptor, as a mechanosuppressive regulator of antitumor T-cell immunity. CD209 was selectively enriched in tumor-infiltrating M2-like macrophages and monocytes, and elevated CD209 expression was associated with poor clinical response to PD-1 blockade and immune dysfunction and exclusion across multiple cancer types. Mechanistically, CD209 directly engaged ICAM-2 on T cells and activated ROCK1–ERM signaling. This interaction increased T-cell cortical stiffness, destabilized T cell–antigen presenting cell interactions, and attenuated T-cell receptor signaling. Blocking the CD209–ICAM-2–ERM pathway restored T-cell activation and promoted CD8+ T-cell infiltration and effector function in both in vivo mouse models and ex vivo human tumor systems. Importantly, CD209 blockade enhanced the response to PD-1 inhibition and overcame resistance to PD-1–based immunotherapy in refractory and immunologically “cold” tumor models. Together, these findings define a myeloid-derived mechanical immune checkpoint and reveal T-cell mechanosuppression as a targetable mechanism of tumor immune evasion and immunotherapy resistance.
Authors
- Ce Wang (ORCID: https://orcid.org/0000-0002-9729-9592)
- Xue Xiao (ORCID: https://orcid.org/0000-0001-7820-6920)
- Guoling Huang (ORCID: https://orcid.org/0000-0002-0987-5060)
- Ming Yi
- Ting Pan (ORCID: https://orcid.org/0000-0003-0146-6278)
- Lingyun Feng (ORCID: https://orcid.org/0009-0003-8781-4022)
- Zhen Li (ORCID: https://orcid.org/0000-0003-0333-7699)
- Yangyang Li (ORCID: https://orcid.org/0000-0002-5791-9443)
- Xi Li (ORCID: https://orcid.org/0000-0002-3108-2091)
- Yanyun Du
- Panyin Shu
- Jiaqi Wu
- Ruirui He
- Bo Zeng
- Zhihui Cui
- Yuan Wang (ORCID: https://orcid.org/0009-0006-8359-4802)
- Heping Wang
- Tingting Wang (ORCID: https://orcid.org/0009-0005-8242-6877)
Institutions
- University of Electronic Science and Technology of China (CN)
- Soochow University (CN)
Publication Details
- Journal
- Cancer Research
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1158/0008-5472.can-26-2612
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Department of Science and Technology of Sichuan Province
- National Science Fund for Distinguished Young Scholars